How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance
Understanding how our use of antimicrobial drugs shapes future levels of drug resistance is crucial. Recently, there has been debate over whether an aggressive (i.e., high dose) or more moderate (i.e., lower dose) treatment of individuals will most limit the emergence and spread of resistant bacteri...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2015-09-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/10559 |
id |
doaj-7bce6acf6c1f4bcf903bc4010482c482 |
---|---|
record_format |
Article |
spelling |
doaj-7bce6acf6c1f4bcf903bc4010482c4822021-05-05T00:01:53ZengeLife Sciences Publications LtdeLife2050-084X2015-09-01410.7554/eLife.10559How competition governs whether moderate or aggressive treatment minimizes antibiotic resistanceCaroline Colijn0https://orcid.org/0000-0001-6097-6708Ted Cohen1Department of Mathematics, Imperial College London, London, United KingdomSchool of Public Health, Yale University, New Haven, United StatesUnderstanding how our use of antimicrobial drugs shapes future levels of drug resistance is crucial. Recently, there has been debate over whether an aggressive (i.e., high dose) or more moderate (i.e., lower dose) treatment of individuals will most limit the emergence and spread of resistant bacteria. In this study, we demonstrate how one can understand and resolve these apparently contradictory conclusions. We show that a key determinant of which treatment strategy will perform best at the individual level is the extent of effective competition between resistant and sensitive pathogens within a host. We extend our analysis to the community level, exploring the spectrum between strict inter-strain competition and strain independence. From this perspective as well, we find that the magnitude of effective competition between resistant and sensitive strains determines whether an aggressive approach or moderate approach minimizes the burden of resistance in the population.https://elifesciences.org/articles/10559drug resistanceantibioticmodellingcompetition |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Caroline Colijn Ted Cohen |
spellingShingle |
Caroline Colijn Ted Cohen How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance eLife drug resistance antibiotic modelling competition |
author_facet |
Caroline Colijn Ted Cohen |
author_sort |
Caroline Colijn |
title |
How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance |
title_short |
How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance |
title_full |
How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance |
title_fullStr |
How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance |
title_full_unstemmed |
How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance |
title_sort |
how competition governs whether moderate or aggressive treatment minimizes antibiotic resistance |
publisher |
eLife Sciences Publications Ltd |
series |
eLife |
issn |
2050-084X |
publishDate |
2015-09-01 |
description |
Understanding how our use of antimicrobial drugs shapes future levels of drug resistance is crucial. Recently, there has been debate over whether an aggressive (i.e., high dose) or more moderate (i.e., lower dose) treatment of individuals will most limit the emergence and spread of resistant bacteria. In this study, we demonstrate how one can understand and resolve these apparently contradictory conclusions. We show that a key determinant of which treatment strategy will perform best at the individual level is the extent of effective competition between resistant and sensitive pathogens within a host. We extend our analysis to the community level, exploring the spectrum between strict inter-strain competition and strain independence. From this perspective as well, we find that the magnitude of effective competition between resistant and sensitive strains determines whether an aggressive approach or moderate approach minimizes the burden of resistance in the population. |
topic |
drug resistance antibiotic modelling competition |
url |
https://elifesciences.org/articles/10559 |
work_keys_str_mv |
AT carolinecolijn howcompetitiongovernswhethermoderateoraggressivetreatmentminimizesantibioticresistance AT tedcohen howcompetitiongovernswhethermoderateoraggressivetreatmentminimizesantibioticresistance |
_version_ |
1721476627031916544 |